Pasatru (Garetosmab)

Garetosmab is a medicine for adults with fibrodysplasia ossificans progressiva (FOP), a rare disease where bone grows in muscles and other soft tissues. It is given as an infusion into a vein. It works by blocking a signal in the body that tells extra bone to form.

Brand names:Pasatru
Medication

What people taking Pasatru (Garetosmab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Pasatru (Garetosmab) for Myositis Ossificans?

NameHow it went

About Pasatru (Garetosmab)

What It's For

Garetosmab, sold as Pasatru, is a prescription infusion for adults with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare inherited condition in which muscles, tendons and ligaments gradually turn into bone. This bone outside the normal skeleton, called heterotopic ossification (HO), builds up in episodes over the years and progressively locks joints in place, limiting movement. The FDA approved Pasatru in 2026 to reduce the formation of new HO and the number of flare-ups judged by a clinician in adults with FOP. Its safety and effectiveness have not been established in children or teenagers. The other FDA-approved FOP medicine, palovarotene (Sohonos), is a retinoid capsule that works differently and is approved for adults and for children from age 8 in girls and age 10 in boys.

How It Works

FOP is caused by a change in the ACVR1 gene, which carries instructions for a receptor that helps control bone growth. In people with FOP, the altered receptor is switched on by activin A, a signaling protein found throughout the body, and that signal pushes soft tissue to turn into bone. Garetosmab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to activin A and stops it from activating the altered receptor, which reduces the formation of new bone. Its approved role is preventing new HO; it is not described as removing bone that has already formed.

Dosage & Administration

Pasatru is given as an infusion into a vein over about 60 minutes, once every 4 weeks, at a clinic or infusion center. The dose is based on body weight. Treatment usually starts at the higher of two approved doses, and the prescriber may lower it if that dose is not tolerated. Anyone who could become pregnant needs a pregnancy test before the first infusion. If an infusion is missed, it should be given as soon as possible, and the schedule then restarts every 4 weeks from that date.

Side Effects

In the main trial, the most common side effects were abscesses (painful pockets of pus, including in the skin and around teeth), acne, extra hair growth, thinning of the eyebrows or eyelashes, mouth sores and nosebleeds. Abscesses were notably more frequent at the higher dose: about a third of people on it had one, compared with about 1 in 10 on placebo. Some skin and soft tissue infections, including abscesses and cellulitis (a spreading infection of the skin), needed treatment or a hospital stay. Contact the care team promptly about skin redness, pain or swelling, or a fever. Nosebleeds can happen without any injury, and one person in the trials needed hospital care to stop one. Get medical care right away for a nosebleed that is heavy, lasts longer than about 20 minutes and does not stop with usual first aid.

Interactions & Warnings

Pasatru must not be used during pregnancy. In animal studies it caused birth defects and infant deaths at exposures similar to or higher than those from human doses. People who could become pregnant should use effective contraception during treatment and for 6 months after the last dose. If pregnancy occurs, stop treatment and contact the prescriber immediately. Breastfeeding is not recommended during treatment or for 6 months afterward. Animal studies also suggest it may reduce male fertility, which is worth discussing before starting if future children matter to you. The prescribing information does not list specific drug interactions, but the care team should still know about every medicine and supplement you take.

What to Expect

Pasatru aims to slow the disease by preventing new bone, not to restore movement already lost. In the 56-week trial of 63 adults, the placebo group developed 19 new bone lesions, compared with 2 in the higher-dose group and 1 in the lower-dose group. Clinician-assessed flare-ups fell sharply at the higher dose (9 compared with 66 on placebo) but not clearly at the lower dose, and the share of people reporting flare-ups themselves did not differ significantly from placebo. Because new bone in the trial was counted on low-dose whole-body CT (computed tomography) scans, the benefit may not be something a person feels from month to month. Treatment involves an infusion visit every 4 weeks with no set stopping point on the label. The approval rests on one small trial, as is common in ultra-rare diseases, so how well it works and how safe it is over many years are still being studied.

Questions to Ask Your Doctor

  1. 1.Is Pasatru or palovarotene a better fit for me, and why?
  2. 2.How will we judge whether it is working, and will I need scans to check for new bone?
  3. 3.What contraception plan should I use during treatment and for 6 months after, and what happens if I want to have children later?
  4. 4.What should I do if I notice a skin infection or a nosebleed that won't stop, and who do I call after hours?
  5. 5.Where will I get my infusions, and what happens if I need to miss one?

Last reviewed • Oct 2026

Educational content, not medical advice.